QualityStocks Stock Newsletters Archives - Page 1782 of 1818

MondayJul 24, 2006 11:41 am

Elgrande International, Inc. has a Winning Team in Place

EGDI – Elgrande International, Inc.Elgrande International (OTCBB: EGDI) has a winning team in place. Michael F. Holloran - President and Chief Executive Officer Mr. Holloran brings to Elgrande a wealth of senior management experience spanning 32 years, including 22 years with the Beak International Group spearheading strategic corporate expansion into key international markets, primarily within Southeast Asia. He has served as a technical advisor to the Asian Development Bank, and the governments of Indonesia, Malaysia and the Philippines. He has held outside directorships, advisory board positions and committee memberships with several prominent North American institutions. He has a Masters degree…

MondayJul 24, 2006 11:36 am

StockGuru Welcomes The Immune Response Corporation (OTCBB: IMNR)

StockGuru Welcomes The Immune Response Corporation (OTCBB: IMNR) View the StockGuru Profile for The Immune Response Corporation: http://www.stockguru.com/profiles/imnr/ The Immune Response Corporation The Immune Response Corporation (OTCBB: IMNR) is a development stage biotechnology company with two products in Phase II clinical trials, one that targets multiple sclerosis (MS) and another that targets HIV/AIDS. These drugs act by stimulating the body’s immune system to slow or stop disease progression through mechanisms of action that differ from existing drugs. These diseases have large patient populations and substantial room for improvement over current therapies. If successful, these drugs could be used alone or…

SundayJul 23, 2006 11:44 am

StockGuru Blog: IncreMental Advantage Initiates Coverage of The Immune Response Corporation – Price Target of $0.09 Per Share Accumulate Rating

IMNR - The Immune Response Corporation IncreMental Advantage, an equity research firm, has initiated coverage of The Immune Response Corporation (OTCBB: IMNR) with an Accumulate rating.“The current market capitalization is only $13.1 million. It is unusual to find such a company with two novel products in Phase II clinical trials.” “We believe the Company’s clinical programs and valuation justify a market capitalization of $200 million to $225 million. If we divide market valuation by the total number of shares outstanding at this time (current), the valuation is $0.31 to $0.38 per share. Dividing market capitalization by fully diluted shares outstanding…

SundayJul 23, 2006 11:26 am

StockGuru Blog: THE IMMUNE RESPONSE CORPORATION If You’ve Overlooked our Recent Releases Rely on Our Remedy – A Reliable Review!

IMNR - The Immune Response CorporationThe Immune Response Corporation was founded in 1986 by Dr. Jonas Salk, the developer of the first polio vaccine. The Immune Response Corporation is a development stage biotechnology company with two products in Phase II clinical trials, one that targets multiple sclerosis (MS) and another that targets HIV/AIDS. If successful, these drugs could be used alone or in combination with other drugs, giving multibillion dollar sales potential. Other autoimmune diseases that IMNR may seek to target are Rheumatoid arthritis and Psoriasis. For a detailed understanding of this biotech company review the presentation that was given…

SundayJul 23, 2006 11:10 am

July 24th CEOcast Weekly Newsletter

07/23/2006 VOLUME 248 Companies featured in the current edition of the newsletter: ADSX, ASPN, CDGT, CPPT, EMIS, ENZ, FLWE, FSN, GSHF, HSOA, HMWM, NVLT, POIG, QTXB, RTK, SOG, USAT It was another brutal week for technology and small-cap stocks, as investors continue to demonstrate their conservative bent. Coming off last week’s three-day drubbing, the markets showed little resilience as a series of high-profile companies reported disappointing earnings, which did little to offset rising tensions overseas and increasing oil prices. The Dow was able to end the week higher by 129 points, increasing its annual gains to 1.4%. The Nasdaq declined…

SaturdayJul 22, 2006 11:36 am

StockGuru Blog: The Immune Response Corporation – Multiple Sclerosis Important Advancements Phase IIb Clinical Trials Scheduled

IMNR - The Immune Response CorporationImportant Phase IIb Trials Set to Begin for MS Treatment - NeuroVax NeuroVax Phase IIb clinical trial is scheduled to begin in early Fall 2006. The trial is designed as a double-blind, placebo controlled study and is expect to enroll about 200 treatment naïve patients in Eastern Europe. In early clinical testing, NeuroVax has been shown to stimulate strong, disease-specific cell-mediated immunity in nearly all patients treated. 3Q:06. There are currently several approved therapeutics for the treatment of MS. These treatments have been shown (1) to reduce annual relapse rates and (2) reduce incidence of…

SaturdayJul 22, 2006 11:26 am

StockGuru Blog: Immune Response Maintains Its Own Manufacturing Facility

IMNR - The Immune Response CorporationImmune Response has its own state-of-the-art manufacturing plant in King of Prussia, Pennsylvania, to make IR103 and NeuroVax for clinical trials. This is one of the few facilities in the world that can produce large quantities of live HIV vaccines. Peter Lowry, Vice President of Manufacturing, is currently responsible for all manufacturing and quality operations at the King of Prussia, Pennsylvania facility. Mr. Lowry joined Immune Response in June 1995, and has over 15 years experience in biopharmaceutical research, bioprocess development, and large scale GMP manufacturing. The 52,500 square foot plant can be scaled up…

FridayJul 21, 2006 11:26 am

Immune Response Corp. Uses the Immune System to Treat Disease: Multiple Sclerosis and HIV/AIDS

IMNR - The Immune Response Corporation The Immune Response Corporation was founded in 1986 by Dr. Jonas Salk, the developer of the first polio vaccine. Therapies in development at IMNR are based on using the immune system to treat diseases. This includes two autoimmune diseases: HIV/AIDS, multiple sclerosis (MS). These therapies include other autoimmune diseases as well.Successful commercialization of discoveries championed by Immune Response would be a ground breaking advance in the treatment of these diseases. NeuroVax Vaccine for Multiple Sclerosis IMNR’s multiple sclerosis product, NeuroVax. This product is currently in Phase II clinical trials. One of the causes of…

FridayJul 21, 2006 11:25 am

StockGuru Trade Alert: CVCP Up More than 35% Since Coverage Started; Volume up 835% Since Coverage Started; Today – New 52 Week High; Yesterday – All Time Volume High of 79,370 Shares

StockGuru Trade Alert: CVCP Up More than 35% Since Coverage Started Volume up 835% Since Coverage Started Today - New 52 Week High Yesterday - All Time Volume High of 79,370 Shares Cavico Corporation (OTC: CVCP) Ten Days Prior to StockGuru Start: 6/27/2006 1.7 0 6/28/2006 1.7 6,680 6/29/2006 1.75 1,240 6/30/2006 1.6 1,970 7/3/2006 1.6 2,460 7/5/2006 1.65 2,900 7/6/2006 1.65 0 7/7/2006 1.65 150 7/11/2006 1.92 6,770 7/12/2006 1.98 11,090 7/13/2006 2.1 3,630 7/14/2006 2.35 23,940 Volume Avg: 5,415 First Week of StockGuru Coverage: 7/17/2006 2.48 58,680 7/18/2006 2.69 29,240 7/19/2006 2.73 13,760 7/20/2006 2.74 79,370 Volume Avg:…

FridayJul 21, 2006 11:21 am

StockGuru First Look: The Immune Response Corporation (OTCBB: IMNR)

StockGuru First Look: The Immune Response Corporation (OTCBB: IMNR) Look out for More Information on our Newest Profile Later this Weekend! A Link to View the Profile is Below: The Immune Response Corporation (OTCBB: IMNR) View the StockGuru Profile for The Immune Response Corporation: http://www.stockguru.com/profiles/imnr/ We Invite you to Visit the All New StockGuru Blog! Here you will find updates on all our covered companies, including Profiled Companies and StockGuru Picks. Click HERE to visit the Blog, or go to: http://stockguru.com/blog/ StockGuru.com is owned and operated by Pentony Enterprises LLC, 9555 Lebanon Road, Suite 103, Frisco, Texas 75035. Telephone: (214)…

Site Search

Company Search

Category: QualityStocks Stock Newsletters